S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Biden, Dems prevail as Senate OKs $1.9T virus relief bill
Black landowner digs in against land grab for oil pipeline
Russia scores points with vaccine diplomacy, but snags arise
Opponents suspect environmental racism in pipeline project
pixel
GOP pushes bills to allow social media 'censorship' lawsuits
Chinese exports surge as global demand recovers from virus
Escalating violence ups pressure for Myanmar sanctions
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Biden, Dems prevail as Senate OKs $1.9T virus relief bill
Black landowner digs in against land grab for oil pipeline
Russia scores points with vaccine diplomacy, but snags arise
Opponents suspect environmental racism in pipeline project
pixel
GOP pushes bills to allow social media 'censorship' lawsuits
Chinese exports surge as global demand recovers from virus
Escalating violence ups pressure for Myanmar sanctions
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Biden, Dems prevail as Senate OKs $1.9T virus relief bill
Black landowner digs in against land grab for oil pipeline
Russia scores points with vaccine diplomacy, but snags arise
Opponents suspect environmental racism in pipeline project
pixel
GOP pushes bills to allow social media 'censorship' lawsuits
Chinese exports surge as global demand recovers from virus
Escalating violence ups pressure for Myanmar sanctions
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Biden, Dems prevail as Senate OKs $1.9T virus relief bill
Black landowner digs in against land grab for oil pipeline
Russia scores points with vaccine diplomacy, but snags arise
Opponents suspect environmental racism in pipeline project
pixel
GOP pushes bills to allow social media 'censorship' lawsuits
Chinese exports surge as global demand recovers from virus
Escalating violence ups pressure for Myanmar sanctions
pixel
Log in
NASDAQ:AIKI

AIkido Pharma Stock Forecast, Price & News

Searched 588 Times  
Notice: This company has been marked as potentially delisted and may not be actively trading.
$1.06
+0.05 (+4.95 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.86
Now: $1.06▼
$1.09
50-Day Range
$1.01
MA: $1.60▼
$2.35
52-Week Range
$0.47
Now: $1.06▼
$5.52
Volume11.66 million shs
Average Volume22.53 million shs
Market Capitalization$86.70 million
P/E RatioN/A
Dividend YieldN/A
Beta1.92
AIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified commercialization platform for protected technologies. The firm's activities include the acquisition and development of patents through internal or external research and development. Its patent portfolio consists of patents in the fields of wireless communications, satellite, solar and radio frequency, as well as 2 U.S. patents in pharmaceutical technology. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.

Headlines

AIkido Pharma Inc. Updates Announcement of Webcast Link for the H.C. Wainwright Global Life Sciences Conference (Virtual Event)
March 4, 2021 |  finance.yahoo.com
AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)
March 1, 2021 |  finance.yahoo.com
AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering
February 23, 2021 |  finance.yahoo.com
AIkido Pharma Provides Update On Antiviral Platform; Says New Compounds Being Tested Against Influenza With SARS-CoV-2 Testing In The Future
February 22, 2021 |  benzinga.com
AIkido Pharma Provides Update on its Antiviral Platform, Including the Virus That Causes COVID-19
February 22, 2021 |  finance.yahoo.com
AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock
February 19, 2021 |  finance.yahoo.com
AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million
February 16, 2021 |  prnewswire.com
AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock
February 16, 2021 |  finance.yahoo.com
AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment
February 16, 2021 |  finance.yahoo.com
AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board
February 3, 2021 |  finance.yahoo.com
AIkido Pharma Adds Inventor Dr. Neil H. Bander, M.D. to Scientific Advisory Board
February 2, 2021 |  prnewswire.com
Aikido Pharma Secures Early Interest in Next Generation Radiotherapy
February 1, 2021 |  finance.yahoo.com
Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications
January 11, 2021 |  finance.yahoo.com
Why Change Healthcare, Isoray And Alkido Are Moving Today
January 6, 2021 |  msn.com
AIkido Pharma Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer
December 9, 2020 |  finance.yahoo.com
AIkido Pharma Inc. Announces Results of 2020 Annual Stockholder Meeting
November 20, 2020 |  feeds.benzinga.com
IL-23 Inhibitors Take Over the US Psoriasis Switching Market at the Expense of the IL-17 and TNF Inhibitors - PRNewswire
November 17, 2020 |  prnewswire.com
AIkido Pharma Inc. Announces Publication of Favorable Peer Reviewed Study of Newly Licensed Antiviral Compounds
November 13, 2020 |  finance.yahoo.com
Arena Pharma (ARNA) Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis, Reports Compelling Topline Results from Phase 2b ADVISE Trial - StreetInsider.com
November 9, 2020 |  streetinsider.com
Increased Biosimilar Prescribing and New Subcutaneous Formulations Are Poised to Impact Biologic Switching in the EU Inflammatory Bowel Disease Market, According to Spherix Global Insights - PRNewswire
November 9, 2020 |  prnewswire.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AIKI
Previous Symbol
CUSIPN/A
CIK12239
Webwww.spherix.com
Phone(703) 992-9325
Employees3
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio59.57
Quick Ratio59.57

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$10,000.00
Price / Sales8,670.27
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.18 per share
Price / Book0.49

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-4,180,000.00
Net MarginsN/A
Return on Equity-50.69%
Return on Assets-49.20%

Miscellaneous

Outstanding Shares81,795,000
Market Cap$86.70 million
Next Earnings Date5/12/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.63 out of 5 stars

Medical Sector

1318th out of 1,968 stocks

Commercial Physical Research Industry

24th out of 42 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Receive AIKI News and Ratings via Email

Sign-up to receive the latest news and ratings for AIKI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AIkido Pharma (NASDAQ:AIKI) Frequently Asked Questions

What stocks does MarketBeat like better than AIkido Pharma?

Wall Street analysts have given AIkido Pharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AIkido Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AIkido Pharma?

AIkido Pharma saw a decrease in short interest during the month of February. As of February 12th, there was short interest totaling 690,400 shares, a decrease of 41.5% from the January 28th total of 1,180,000 shares. Based on an average trading volume of 16,430,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.0% of the shares of the company are sold short.
View AIkido Pharma's Short Interest.

When is AIkido Pharma's next earnings date?

AIkido Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, May 12th 2021.
View our earnings forecast for AIkido Pharma.

Who are AIkido Pharma's key executives?

AIkido Pharma's management team includes the following people:
  • Anthony C. Hayes, CEO, Principal Financial Officer & Director
  • Tom Wilkie, Chief Science Officer
  • Jane H. Behrmann, Office Manager

Who are some of AIkido Pharma's key competitors?

Some companies that are related to AIkido Pharma include Luna Innovations (LUNA), Bioanalytical Systems (BASI), Auxly Cannabis Group (CBWTF), Eloxx Pharmaceuticals (ELOX), Pieris Pharmaceuticals (PIRS), Cleveland BioLabs (CBLI), Bioqual (BIOQ), NanoViricides (NNVC), Inhibitor Therapeutics (INTI), HedgePath Pharmaceuticals (HPPI), Tenax Therapeutics (TENX), ProMIS Neurosciences (ARFXF), U.S. Stem Cell (USRM), Vitality Biopharma (VBIO) and Protalex (PRTX).
View all of AIKI's competitors.

What other stocks do shareholders of AIkido Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIkido Pharma investors own include Biocept (BIOC), AIM ImmunoTech (AIM), CHF Solutions (CHFS), Foresight Autonomous (FRSX), iBio (IBIO), Exela Technologies (XELA), Bionano Genomics (BNGO), Check-Cap (CHEK), Digital Ally (DGLY) and Purple Biotech (KTOV).

What is AIkido Pharma's stock symbol?

AIkido Pharma trades on the NASDAQ under the ticker symbol "AIKI."

Who are AIkido Pharma's major shareholders?

AIkido Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.25%).
View institutional ownership trends for AIkido Pharma.

Which major investors are buying AIkido Pharma stock?

AIKI stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for AIkido Pharma or or view top insider-buying stocks.

What is AIkido Pharma's stock price today?

One share of AIKI stock can currently be purchased for approximately $1.06.

How much money does AIkido Pharma make?

AIkido Pharma has a market capitalization of $86.70 million and generates $10,000.00 in revenue each year.

How many employees does AIkido Pharma have?

AIkido Pharma employs 3 workers across the globe.

What is AIkido Pharma's official website?

The official website for AIkido Pharma is www.spherix.com.

Where are AIkido Pharma's headquarters?

AIkido Pharma is headquartered at ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY, 10020.

How can I contact AIkido Pharma?

AIkido Pharma's mailing address is ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY, 10020. The business services provider can be reached via phone at (703) 992-9325 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.